Résultats de la recherche - Pallavi Sachdev
-
1
Characterization of Lewy Body copathology in early AD clinical trial population demonstrates similarities and differences compared to natural history studies in Alzheimer's disease...
Publié 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
2
A de novo ‐assisted strategy to identify novel lncRNA‐encoded peptides in cerebrospinal fluid of demented subjects with or without amyloid positivity
Publié 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
3
Identifying differentially expressed proteins between amyloid positive and amyloid negative subjects based on Alamar multiplex assay data using MissionAD samples
Publié 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
4
Long‐Term Effects of Lecanemab on Biomarkers of Neurodegeneration in Plasma
Publié 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
5
"Paradoxical” Cerebral Volume Changes in Anti‐Amyloid Immunotherapy Trials
Publié 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
6
Neuro‐Dynamic Quantitative Systems Pharmacology (Qsp) Model Supports Continued Lecanemab Treatment With Maintenance Dosing For Alzheimer’s Disease
Publié 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
7
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
Publié 2026Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
8
Combining CSF MTBR‐tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease
Publié 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
9
Target Engagement of Lecanemab on CSF Aβ Protofibril Toxic Species in Clarity AD
Publié 2025Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
10
Lecanemab Slows Amyloid‐Induced Tau Pathology as Supported by CSF MTBR‐tau243 in Clarity AD
Publié 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
11
Prediction of regional brain tau levels in early Alzheimer’s disease using plasma pTau217
Publié 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
12
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
Publié 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
13
In vivo biomarkers of GABAergic function in epileptic rats treated with the GAT‐1 inhibitor E2730
Publié 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso -
14
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid
Publié 2024Fuente: Wiley Open AccessTipo de material: Artículo Open AccessAcceso al recurso